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Peripheral neuropathy (PN) is present in 30-50% of individuals with Immunoglobulin M Monoclonal 
gammopathy of unknown significance (IgM MGUS) and Waldenstrom Macroglobulinemia (WM). In 
approximately 50% of these cases, this is due to IgM anti-myelin-associated glycoprotein (MAG) 
paraprotein-associated peripheral neuropathy (anti-MAG PN)1,2. Anti-MAG PN typically presents as a 
chronic demyelinating disorder with progressive ataxia, tremor and sensory disturbance. The typical 
electrophysiological features associated with anti-MAG PN consist of slowed motor conduction 
velocities with a disproportionate prolongation of the distal motor latency, and significant involvement 
of sensory nerves.1,3 By definition, a serum IgM paraprotein and anti-MAG antibodies are present.  Up 
to 50% of patients develop significant disability after 10-15 years. Progressive disease-related 
disability is an indication to start treatment. However, while there is some evidence supporting clinical 
benefit of rituximab,1,4 there is currently no consensus on the optimal treatment approach for anti-MAG 
PN and there is a high clinical need for effective therapies1.    
IgM paraproteinemia is a hallmark of WM and IgM MGUS. WM is an indolent B-cell 
malignancy with lymphoplasmacytic differentiation typically localized in the bone marrow (BM), 
while IgM MGUS is defined as asymptomatic IgM paraproteinemia with < 10% BM infiltration by 
lymphoplasmacytic cells.5 The term "IgM related disease" is reserved for IgM MGUS with symptoms 
that are attributable to the paraprotein, such as cryoglobulinaemia, neuropathy and cold agglutinin 
disease5. Individuals with IgM MGUS are at increased risk for developing B-cell malignancies, mainly 
WM6,7.  
Recently, a recurrent somatic point mutation of the myeloid differentiation factor 88 (MYD88) 
gene, leading to an amino-acid change from leucine to proline (L265P), has been reported in the vast 
majority (> 90%) of WM patients and approximately 50% of IgM MGUS patients. The mutation is 
absent in healthy donors and multiple myeloma 8,9. MYD88 mutations, in particular the MYD88 L265P 
hot spot mutation, are found in a small subset of the aggressive large-cell B-cell lymphomas, including 
activated B-cell type diffuse large B-cell lymphoma and primary central nervous system lymphoma. 
10,11.  Among indolent small-cell B-cell lymphomas, the MYD88 L265P mutation is largely confined to 
WM.8 MYD88 is an adaptor protein of the interleukin-1R and toll-like receptor signalling pathways 
that ultimately lead to activation of nuclear factor-κB (NF-κB) and Janus kinase (JAK)/signal 
transducer and activator of transcription 3 (STAT3). The MYD88 L265P mutation results in aberrant 
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activation of these pathways and is considered the central driver mutation of WM and a diagnostic 
signature of the disease. In individuals with IgM MGUS, the presence of MYD88 L265P is associated 
with a higher risk of progression to WM7. In WM patients, treatment with ibrutinib, an oral Bruton's 
Tyrosine Kinase (BTK) inhibitor is less effective in WM patients with wild-type MYD88 than in those 
with MYD88 L265P12. The incidence of MYD88 L265P is unknown in most IgM related disorders, with 
the exception of cold agglutinin disease (CAD), a chronic hemolytic disorder associated with IgM 
paraproteinemia. In CAD, MYD88 L265P was absent in all tested patients, which confirmed it as a 
distinct entity from WM.13   
Thus far, the mutational status of MYD88 has not been studied in IgM related PN. In the 
current study, we have found a high prevalence of MYD88 L265P in the BM of anti-MAG PN-patients. 
 
Our study comprises 22 patients with anti-MAG PN. Inclusion criteria were: 1) presence of 
IgM paraprotein in the serum; 2) a positive serum IgM MAG-antibody test; 3) a confirmed clinical 
diagnosis of anti-MAG neuropathy by a neurologist specialized in peripheral nerve disorders, including 
electromyography (EMG); 4) availability of a BM sample for mutational analysis. Eligible patients 
were included at four centres: three in the Netherlands (AZN, AMC, and UMCU), and one in the UK 
(UCLH). Anti-MAG-antibody testing was performed per standard clinical care at each individual 
centre, using a commercially available ELISA (Bühlmann-Laboratories, Switzerland) with a cut-off 
point of at least 1500 Bühlmann titer units. Flow cytometry of the bone marrow aspirate for the 
detection of clonal B-cells was performed per standard clinical care in the subset of Dutch patients. 
MYD88 L265P mutation analysis was performed at two centres (UCLH and AMC) on DNA extracted 
from either stored BM aspirates or trephine biopsy specimens, using an allele specific PCR as 
described previously 10.  In samples that tested negative for the mutation, the presence of a B-cell clone 
was assessed using multiplex PCRs for the detection of B-cell receptor rearrangements 14.  
The clinical characteristics of the patients, including neurological findings and relevant 
biochemical parameters, as well as the results of the mutation analysis are summarized in table 1. The 
MYD88 L265P mutation was detected in 13/22 patients (59%). Of the 9 patients (41%) that tested 
negative for the mutation, the presence of a B-cell clone was confirmed by rearrangement testing in 2 
patients. In the other 7 patients that tested negative for the mutation, a clonal B cell population could 
not be detected.  
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Our study demonstrates that the MYD88 L265P mutation is highly prevalent in a cohort of 
well-characterized anti-MAG PN patients.  The detected mutational rate of 59% most likely represents 
an underestimate since the tumour load was generally very low, as shown by the low quantity of clonal 
B-cells as detected by flow cytometry and negative B-cell receptor rearrangement-based clonality 
studies in 7/9 mutation negative patients. This indicates a very low frequency of neoplastic B cells in 
these samples, which may have precluded MYD88 L265P detection. Indeed, the reported prevalence of 
MYD88 L265P in IgM MGUS is highly variable (10-87%) which most likely relates to sensitivity 
issues in the setting of a low clonal B-cell burden.9  
Our current results establish that the majority of anti-MAG PN cases contain the WM 
signature MYD88 L265P mutation. Furthermore, like B cells in WM, anti-MAG PN B cells have been 
shown to represent post-germinal center memory B cells that have undergone somatic mutation of their 
immunoglobulin-variable genes15.  Low-titer anti-MAG antibodies have been found in up to 40% of 
WM/IgM MGUS patients2.  Taken together, these data strongly suggest a pathogenetic link of IgM 
anti-MAG paraprotein-associated PN with WM. This supports the initiation of clinical trials for anti-
MAG PN using agents that have proven efficacy in WM. Specifically, novel targeted agents with little 
(neuro-) toxicity such as the novel oral proteasome inhibitors or BTK inhibitors1,12 could  be of great 
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Table 1:  
 





n.t:  Not tested 
 
A     While bone marrow histology was performed in all cases, additional flow -cytometry of the bone 
 marrow was only available in a subset.  
 
B   Clinical phenotype 
 1: Sensorimotor polyneuropathy, characterized by sensory disturbances, ataxia and ankle dorsiflexor 
 weakness 
 2: Pure sensory polyneuropathy characterized by sensory disturbance and/or ataxia 
 
C   EMG result  
 1: Nerve conduction velocities consistent with a demyelinating polyneuropathy with a prolonged distal 
 motor latency 































M 72 MGUS n.t.  < 3 1 1 +  
F 43 MGUS n.t.  7 2 1 +  
M 70 MGUS n.t.  <3 1 1 +  
F 74 MGUS n.t.  <3 1 1 +  
F 72 MGUS n.t.  9 1 1 - + 
M 62 MGUS n.t.  10 1 1 +  
M 62 MGUS n.t.  4 1 1 - - 
M 71 WM n.t.  3 1 1 +  
M 66 MGUS 2% 5 1 1 +  
M 73 MGUS Negative 7,6 2 2 +  
M 71 MGUS 1% 5,7 1 1 - + 
F 77 MGUS Negative 8,7 2 2 - - 
M 64 MGUS 3% 16 1 1 +  
M 64 MGUS Negative 1,7 1 1 - - 
F 79 MGUS 4% 5,7 1 1 +  
M 67 MGUS Negative 2,3 1 1 - - 
F 59 MGUS n.t. 4,7 1 1 +  
M 73 MGUS Negative  2,3 1 1 - - 
M 76 MGUS Negative 8,1 1 1 - - 
F 66 MGUS <1% 5,4 1 1 - - 
F 75 MGUS 5% 3.16 1 1 +  
M 70 MGUS Negative 0.6 1 1 +  
